Kyowa Kirin accepted the evaluation results for Nephoxil

Negotiations with the NHIS

Kyowa Kirin expects to strengthen its position in the chronic renal failure treatment market

It is known that Kyowa Kirin Korea's hyperphosphatemia treatment 'Nephoxil 500mg' accepted the HIRA evaluation results.

 

Accordingly, this drug is expected to move to the negotiation stage with the NHIS.

 

Nephoxil is used for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis.

 

Expectations are high because it is a product of Kyowa Kirin Korea, which stands out in the chronic kidney disease patient treatment market with Nesp·Regpara.

 

Currently, non-calcium drugs such as Renvela are preferred in the hyperphosphatemia treatment market for hemodialysis patients, and the introduction of Nephoxil is expected to change the market structure.

 

According to the industry on the 16th, Korea Kyowa Kirin of Nephoxil Capsule, which received conditional pass results at the Pharmaceutical Review Board meeting on the 6th, accepted the evaluation results.

 

The HIRA judged that it was appropriate to receive reimbursement for this drug, which is used for hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis when it was accepted below the estimated amount.

 

In other words, it is interpreted that the Korea Kyowa Kirin side accepted less than the estimated amount suggested by HIRA.

 

The proposed valuation seems to have been based on the price of non-calcium-based drugs like Nephoxil.

 

Calcium-based drugs and non-calcium-based drugs are used to treat hyperphosphatemia in dialysis patients.

 

Although calcium-based drugs are relatively inexpensive, non-calcium-based drugs are increasing in use due to the risk of causing vascular calcification.

 

Representative items of non-calcium-based drugs include Renvela, Invela (SK Chemicals), and Fosrenol (JW Pharmaceutical).

 

As domestic drugs containing Sevelamer are released one after another, the price has become much cheaper.

 

Accepting this evaluation result, Nephoxil will proceed with negotiations with NHIS in the future.

 

When the negotiations are completed, they will go through a report to the Health Insurance Policy Deliberation Committee of the Ministry of Health and Welfare and be listed on the list of benefits.

 

In the market, as Kyowa Kirin Korea stands out in the domestic chronic renal failure drug market, Nephoxil is also expected to settle down early.

 

Kyowa Kirin Korea is recording a high market share with Nesp, a treatment for anemia in patients with chronic kidney disease, and Regpara, a treatment for secondary hyperparathyroidism in patients with chronic kidney disease.

 

Furthermore, Kyowa Kirin took the top spot in the hyperphosphatemia treatment market with Renagel before Renvela was launched in Korea.

 

The domestic supply of Renagel was discontinued in 2015.

 

Renagel and Renvela are drugs developed by Genzyme, and it is rumored that Renagel withdrew from the market after Renvela was supplied through Sanofi in Korea.

 

From the perspective of Kyowa Kirin Korea, Nephoxil is expected to serve as an opportunity to further strengthen its position in the chronic renal failure patient treatment market.

 

Meanwhile, Nephoxil received domestic approval in May last year.